EU Could Approve BioNTech, Moderna Vaccines in December

Elias Hubbard
November 22, 2020

With a December 31 deadline looming, European Commission President Ursula von der Leyen said Friday the bloc and Britain are making "better progress" in negotiating final Brexit issues that will lead to a trade deal.

Speaking on Thursday about the ongoing second wave that is hitting Europe, which has forced many countries to re-introduce lockdown measures, von der Leyen said that "expectations have to be managed".

The EU could approve the COVID-19 vaccines developed by Pfizer Inc (NYSE:PFE) and Moderna Therapeutics Inc (NASDAQ:MRNA) as early as December.

U.S. biotech company Moderna has said its experimental vaccine is 95 percent effective.

"We need the same ambition at the global level if we are to protect humanity against the global threat", said von der Leyen.

Von der Leyen sounded optimistic about the movement, but realistic about the work still ahead in negotiations.

The European Commission has agreed deals with several pharmaceutical companies including BioNTech and Pfizer to buy millions of doses of vaccines on behalf of all EU member states.

"And if all proceeds with no problems".

Earlier on Thursday, Ugur Sahin, the manager of BioNTech, told AFP news agency that its vaccine might get authorization and also be dispersed in America and the European Union earlier 2021.

"There is a chance that we can receive approval from the USA or Europe or both regions this year still", said Sahin, who is also BioNTech's chief executive.

She also expressed caution regarding the potential use of the Russian vaccine Sputnik V, which first needs to gain EMA approval.

"It is clear that with a delay this is not going to limit the total amount but it is going to slow down delivery", he told AFP, in an interview.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER